| Literature DB >> 32944320 |
Luca Voltolini1, Alessandro Gonfiotti1, Domenico Viggiano2, Sara Borgianni1, Arianna Farronato1, Stefano Bongiolatti1.
Abstract
BACKGROUNDS: The aim of this study was to report our Institutional experience with extended sleeve lobectomy (ESL) in centrally located non-small cell lung cancer (NSCLC), focusing on technical details, post-operative results, recurrence and survival, to determine whether ESL can be accepted as a favorable alternative procedure to pneumonectomy (PN).Entities:
Keywords: Locally-advanced non-small cell lung cancer (NSCLC); bronchoplasty; extended-sleeve lobectomy; pneumonectomy; survival
Year: 2020 PMID: 32944320 PMCID: PMC7475556 DOI: 10.21037/jtd-20-1241
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1Pre-operative CT scan with a typical clinical finding leading of a type C extended sleeve lobectomy (ESL).
Figure 2Division of the intersegmental plane between lingula and left upper division with stapler (A). Bronchial anastomosis between the left main bronchus and the upper division bronchus (B1+2 and B3) with running suture (B,C).
Demographic, pre-operative data and clinical stages
| Variable | ESL (n=22) | PNs (n=38) | P |
|---|---|---|---|
| Sex, n (%) | 1 | ||
| Male | 14 (63.6) | 23 (60.5) | |
| Female | 8 (36.4) | 15 (39.5) | |
| Median age | 68.5 (51–79) | 67 (51–83) | 0.17 |
| PS ECOG, n (%) | 0.47 | ||
| 0 | 10 (45.5) | 22 (57.9) | |
| 1 | 11 (50) | 13 (34.2) | |
| 2 | 1 (4.5) | 3 (7.9) | |
| ASA score, n (%) | 0.81 | ||
| 1 | 5 (22.7) | 11 (28.9) | |
| 2 | 3 (13.6) | 6 (15.8) | |
| 3 | 14 (63.6) | 21 (55.3) | |
| mCCI score, n (%) | 0.58 | ||
| 0 | 5 (22.7) | 8 (24.2) | |
| 1 | 7 (31.8) | 16 (42.1) | |
| 2 | 8 (36.4) | 8 (21.1) | |
| 3 | 1 (4.5) | 5 (13.2) | |
| 4 | 1 (4.5) | 1 (2.6) | |
| BMI | 25.5 (20–30.7) | 26.85 (17–40) | 0.43 |
| FEV1% | 77 (56–140) | 84 (38–189) | 0.86 |
| FVC% | 93 (63–155) | 97.5 (49–185) | 0.56 |
| DLCO% | 55 (44–75) | 68.5 (38–117) | 0.18 |
| Clinical stage, n (%) | 0.94 | ||
| Ia | 1 (4.5) | 1 (2.6) | |
| Ib | 0 | 1 (2.6) | |
| IIa | 1 (4.5) | 3 (7.9) | |
| IIb | 7 (31.8) | 9 (23.7) | |
| IIIa | 11 (50) | 20 (52.6) | |
| IIIb | 2 (9.1) | 3 (7.9) | |
| IV | 0 | 1 (2.6) | |
| Neo-adjuvant chemotherapy, n (%) | 7 (31.8) | 12 (31.6) | 0.77 |
ESL, extended sleeve lobectomy; PNs, pneumonectomies; PS ECOG, Performance Status Eastern Cooperative Oncological Group; ASA, American Society of Anesthesiologists; mCCI, modified Charlson Comorbidity Index; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide.
Surgical procedure, post-operative and oncological outcomes
| Variable | ESL (n=22) |
|---|---|
| Surgical procedure, n (%) | |
| Type A | 8 (36.4) |
| Type B | 1 (4.5) |
| Type C | 13 (59.1) |
| Double sleeve | 6 (27.3) |
| Istology, n (%) | |
| ADC | 8 (36.4) |
| SCC | 14 (63.6) |
| Pathological stage, n (%) | |
| Ia | 2 (9.1) |
| Ib | 1 (4.5) |
| IIa | 2 (9.1) |
| IIb | 2 (9.1) |
| IIIa | 9 (40.9) |
| IIIb | 6 (27.3) |
| pN, n (%) | |
| 0 | 5 (22.7) |
| 1 | 6 (27.3) |
| 2 | 11 (50.0) |
| Median hospital stay in days, mean [range] | 10 [6–44] |
| Tumour diameter in cm, mean [range] | 4.3 [1.3–8] |
| Adjuvant chemotherapy, n (%) | 11 (50.0) |
| Median follow-up in months, mean [range] | 21 [4–57] |
| Recurrence, n (%) | |
| Local | 2 (9.1) |
| Distant | 8 (36.4) |
| Both | 2 (9.1) |
ESL, extended sleeve lobectomy; ADC, adenocarcinoma; SCC, squamous cell carcinoma; pN, pathological nodal status.
Figure 3Fiber-optic bronchoscopy (A) of an extended sleeve lobectomy (ESL) type A and post-operative CT scan of ESL type C (B).
Figure 4Overall survival curve comparing extended sleeve lobectomy (ESL) and pneumonectomies (PNs) performed in the same period.